×
About 19,896 results
HER2+ Colorectal and Gastric/GEJ Cancers Demonstrate Responses to Fam-Trastuzumab Deruxtecan Therapy
https://www.targetedonc.com/view/her2-colorectal-and-gastric-gej-cancers-demonstrate-responses-to-fam-trastuzumab-deruxtecan

May 29th, 2020 - Data from 2 phase 2 trials involving fam-trastuzumab deruxtecan-nxki (Enhertu) revealed the agent’s ability to induce responses in patients with HER2-positive metastatic colorectal cancer (CRC) and advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Both studies had results presented at the 2020 ASCO Virtual Scientific Program.

PyL PET Tracer May Be Superior to Standard Imaging for Prostate Cancer
https://www.targetedonc.com/view/pyl-pet-tracer-may-be-superior-to-standard-imaging-for-prostate-cancer

May 29th, 2020 - PSMA-targeted 18F-DCFPyL-PET/CT imaging demonstrated excellent diagnostic performance in men with biochemically relapsed prostate cancer in terms of a correct localization rate that far exceeded the criteria to meet the primary end point, according to findings from the phase 3 CONDOR trial.

Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma
https://www.onclive.com/onclive-tv/dr-richardson-on-phase-1-data-with-cc92480-in-multiple-myeloma

May 31st, 2020 - Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses phase 1 data (NCT03374085) with CC-92480 in multiple myeloma.

Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL
https://www.onclive.com/onclive-tv/dr-wang-on-correlative-data-from-the-zuma2-trial-in-mcl

May 31st, 2020 - Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer
https://www.onclive.com/onclive-tv/dr-poveda-on-the-results-of-the-solo2-trial-in-ovarian-cancer

May 31st, 2020 - Andres Poveda, MD, Initia Oncology, Hospital Quironsalud, in Valencia, Spain, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.

Tepotinib Displays Durable Clinical Benefit in METex14-Altered NSCLC
https://www.onclive.com/conference-coverage/asco-2020/tepotinib-displays-durable-clinical-benefit-in-metex14altered-nsclc

May 30th, 2020 - The oral, highly selective MET inhibitor tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) who harbor a MET exon 14 (METex14) skipping mutation identified through liquid or tissue biopsy, according to findings from the phase 2 VISION trial (NCT02864992) that were simultaneously presented at the 2020 Virtual Scient...

Alectinib Continues to Maintain Significant OS Benefit in ALK+ NSCLC
https://www.onclive.com/conference-coverage/asco-2020/alectinib-continues-to-maintain-significant-os-benefit-in-emalkem-nsclc

May 30th, 2020 - The highly selective second-generation TKI alectinib (Alecensa) demonstrated a clinically meaningful improvement in overall survival compared with crizotinib (Xalkori) in patients with ALK-positive non–small cell lung cancer (NSCLC), according to updated data from the pivotal phase 3 ALEX trial presented at the 2020 ASCO Virtual Scientific Program.

Dr. Johnson on the Results of the CITYSCAPE Trial in PD-L1+ NSCLC
https://www.onclive.com/conference-coverage/asco-2020/dr-johnson-on-the-results-of-the-cityscape-trial-in-pdl1-nsclc

May 28th, 2020 - Melissa L. Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the results of the phase 2 CITYSCAPE trial in PD-L1–positive non–small cell lung cancer (NSCLC).

KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL
https://www.onclive.com/conference-coverage/asco-2020/ktex19-demonstrates-comparable-pharmacologic-clinical-outcomes-to-approved-therapies-in-mcl

May 29th, 2020 - The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial, according to data presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer
https://www.onclive.com/conference-coverage/asco-2020/frontline-durvalumab-maintains-os-benefit-in-updated-essclc-findings

May 29th, 2020 - The addition of durvalumab (Imfinzi) to standard chemotherapy continued to demonstrate an improvement in overall survival (OS) for patients with treatment-naïve extensive-stage small cell lung cancer (ES-SCLC), according to updated results from the phase 3 CASPIAN study presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

Frontline Pembrolizumab/Axitinib Survival Benefit Upholds in Advanced RCC
https://www.onclive.com/conference-coverage/asco-2020/frontline-pembrolizumabaxitinib-survival-benefit-upholds-in-advanced-rcc

May 29th, 2020 - The combination of pembrolizumab (Keytruda) and axitinib (Inlyta) continued to demonstrate a clinically significant improvement in progression-free and overall survival (OS) compared with sunitinib (Sutent) in patients with previously untreated, advanced renal cell carcinoma (RCC), according to updated findings of the phase 3 KEYNOTE-426 trial that were presented during the 2020 ASCO Virtual Sc...

Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC
https://www.onclive.com/conference-coverage/asco-2020/tislelizumab-frontline-combos-extend-pfs-in-squamous-nsclc

May 29th, 2020 - Combining the anti–PD-1 agent tislelizumab (BGB-A317) with chemotherapy improved progression-free survival (PFS) compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer (NSCLC), according to findings from the phase 3 BGB-A317-307 trial presenting during the 2020 ASCO Virtual Scientific Program.

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL
https://www.onclive.com/conference-coverage/asco-2020/interim-analysis-from-phase-ii-zuma5-study-shows-promise-for-axicel-in-rr-inhl

May 29th, 2020 - An interim analysis of the phase II ZUMA-5 study indicated that axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit, with high rates of overall response rate (ORR) and complete response (CR) observed, as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPC
https://www.onclive.com/conference-coverage/asco-2020/apalutimide-plus-adt-leads-to-significantly-improved-outcomes-in-patients-with-nmcrpc

May 29th, 2020 - Results from the phase III SPARTAN trial showed that apalutamide (Erleada) plus androgen deprivation therapy (ADT) significantly improved overall survival (OS) when compared with ADT plus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to findings presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

Trastuzumab Deruxtecan Shows Promising Clinical Activity in CRC and Gastric/GEJ Tumors
https://www.onclive.com/conference-coverage/asco-2020/trastuzumab-deruxtecan-shows-promising-clinical-activity-in-crc-and-gastric-gej-tumors

May 29th, 2020 - The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer (CRC), as well as in those with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, according to findings from 2 phase 2 trials that were presented at the 2020 ASCO Virtual Scientific Program.

Teclistamab Appears Safe at All Doses for Relapsed/Refractory Myeloma Treatment
https://www.onclive.com/conference-coverage/asco-2020/teclistamab-appears-safe-at-all-doses-for-relapsed-refractory-myeloma-treatment

May 29th, 2020 - Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma, according to a phase I study presented at the ASCO Virtual Scientific Program.

Idecabtagene Vicleucel Highly Active in Heavily Pretreated Myeloma
https://www.onclive.com/conference-coverage/asco-2020/idecabtagene-vicleucel-highly-active-in-heavily-pretreated-myeloma

May 28th, 2020 - The BCMA-targeting CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121) induced a response in nearly three-fourths of patients with heavily pretreated relapsed/refractory multiple myeloma, according to topline findings from the pivotal phase 2 KarMMA trial shared during the 2020 ASCO Virtual Scientific Program.

Off-the-Shelf CAR-T Cell Therapy ALLO-501 Induces High Responses in Relapsed/Refractory B-Cell Lymphomas
https://www.onclive.com/conference-coverage/asco-2020/off-the-shelf-cart-cell-therapy-allo501-induces-high-responses-in-relapsed-refractory-bcell-lymphomas

May 29th, 2020 - The allogeneic chimeric antigen receptor (CAR)-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, has clinical activity and a manageable safety profile in patients with relapsed/refractory large B-cell or follicular lymphoma. The first-in-human findings were presented during the virtual scientific program of the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting.

Pembrolizumab/Chemo Significantly Improves PFS in Frontline PD-L1-High TNBC
https://www.onclive.com/conference-coverage/asco-2020/pembrolizumabchemo-significantly-improves-pfs-in-frontline-pdl1high-tnbc

May 28th, 2020 - Pembrolizumab (Keytruda) in combination with several chemotherapy partners led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone as a first-line treatment for patients with locally recurrent, inoperable, or metastatic triple-negative breast cancer (TNBC) whose tumors expressed PD-L1 (combined positive score [...

HERO Trial Suggests Relugolix to Become New Standard for T-Suppression in Advanced Prostate Cancer
https://www.onclive.com/conference-coverage/asco-2020/hero-trial-suggests-relugolix-to-become-new-standard-for-tsuppression-in-advanced-prostate-cancer

May 29th, 2020 - Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks, fast T-recovery after discontinuation, and a 50% reduction in major adverse cardiovascular events (MACE) in patients with advanced prostate cancer, according to findings from the phase 3 HERO trial, presented at the 2020 ASCO Virtual Scientific Meeting.